Clinical trials: Migraine Prophylaxis
Chronic Migraine
Repetitive Transcranial Magnetic Stimulation in Treatment and Prophylaxis of Chronic Migraine in Patients With no Prophylactic Treatment for the Last 3 Months
Compared with the patients with episodic migraine those with chronic migraine have worst quality of life and more severe headache related disability we investigate Repetitive transcranial magnetic stimulation in treatment and…
- Trial name
- rTMS (NCT06461767)
- Testing
- transcranial magnetic stimulation device
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Sohag University
Migraine
MLD10 in the Prevention of Migraine in Adults
This is a double-blind, placebo-controlled, randomized, multi-center study. Subjects agreeing to participate in the study and meet the entry criteria assessed at the screening visit, will begin a 28 day baseline period to confirm…
- Trial name
- NCT02322333
- Testing
- MLD10
- Where
- 9 sites in United States
- Volunteers
- 157 people
- Sponsor
- Pharmalyte Solutions LLC
Migraine
Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention
The primary objective of the study was to evaluate the effect of erenumab compared to placebo on the change from baseline in monthly migraine days.
- Trial name
- STRIVE (NCT02456740)
- Testing
- Erenumab
- Where
- 129 sites in United States, Austria and 11 more
- Volunteers
- 955 people
- Sponsor
- Amgen
Migraine, Episodic Migraine
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies…
- Conditions
- Migraine, Episodic Migraine, Chronic Migraine, Headache
- Trial name
- EUREkA (NCT07159750)
- Testing
- CGRP antibody or gepant
- Where
- 26 sites in United States, Argentina and 11 more
- Volunteers
- 700 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Migraine, Pain
A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain
A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain.
- Conditions
- Migraine, Pain, Nausea, Vomiting
- Trial name
- NCT03877718
- Testing
- Arm 1: CL-H1T, Arm 2: CL-H1T, Arm 3: Sumatriptan Succinate 100 mg capsule
- Where
- 3 sites in United States
- Volunteers
- 475 people
- Sponsor
- Charleston Laboratories, Inc
Migraine Disorders
A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches
This is a 60 week study including a double-blind phase followed by an open-label phase.
- Trial name
- NCT00168428
- Testing
- Botulinum Toxin Type A
- Where
- 6 sites in United States, Canada and 4 more
- Volunteers
- 705 people
- Sponsor
- Allergan
Migraine
Melatonin for Migraine Prevention
The circadian system with its centre in the hypothalamus is involved in migraine pathophysiology. Whether it plays a pivotal role is not clarified.
- Trial name
- MMP (NCT00849511)
- Testing
- melatonin
- Where
- 2 sites in Norway
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Nordlandssykehuset HF
Migraine Headache
Pilot Study of BOTOX for Migraine Headaches
The purposes of this study are to assess whether subjects treated with BOTOX will: 1. have a decrease in the frequency and intensity of migraine headaches 2. experience improvements in quality of life 3.
- Trial name
- NCT00850421
- Testing
- Botulinum Toxin Type A
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- HealthPartners Institute
Migraine
DP-VPA for Migraine Prophylaxis, a Pilot Efficacy Study
The study will evaluate if DP-VPA, a derivative of valproate (a drug that is commonly used for the prevention of migraine attacks), can reduce the rate of migraine attacks.
- Trial name
- NCT00640965
- Testing
- DP-VPA
- Where
- 6 sites in Israel
- Volunteers
- 40 people
- Sponsor
- D-Pharm Ltd.
Migraine
Real World Data Analysis: Impact of High-Frequency REN Treatments As Migraine Preventive Therapy in Adolescence
This is a post-marketing study investigating the safety and efficacy of the REN device (Nerivio by Theranica, ISRAEL) in adolescents with migraine.
- Trial name
- NCT05769322
- Testing
- Nerivio
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Theranica
Migraine Without Aura, Unilateral Headache
Acupuncture for Migraine Prophylaxis
Hypothesis: Acupuncture obtains an abiding effect on migraine prophylaxis Design: A open-label randomized controlled trial. 249 participants will be included.
- Trial name
- AMP (NCT01687660)
- Testing
- acupuncture
- Where
- China
- Volunteers
- 249 people, healthy volunteers welcome
- Sponsor
- Li ying
Migraine, Prophylaxis
Atogepant in Real Life in Italy (GIANT)
Atogepant is an oral, small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist that has been approved for the preventive treatment of episodic and chronic migraine (>= 4 monthly migraine days) with or without…
- Trial name
- GIANT (NCT06136442)
- Testing
- Atogepant
- Volunteers
- 500 people
- Sponsor
- IRCCS San Raffaele Roma
Episodic Migraine
12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine
To evaluate the safety and tolerability of atogepant 30 mg and 60 mg once a day for the prevention of migraine in participants with episodic migraine.
- Trial name
- NCT03777059
- Testing
- Atogepant
- Where
- 138 sites in United States
- Volunteers
- 910 people
- Sponsor
- Allergan
Migraine
A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention
Randomized, double-blind, placebo-controlled, parallel-group, multicenter study followed by an open-label treatment phase (OLTP).
- Trial name
- NCT02630459
- Testing
- Erenumab
- Where
- 44 sites in Japan
- Volunteers
- 475 people
- Sponsor
- Amgen
Migraine
Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications
This study is being conducted to evaluate the efficacy and tolerability of rimegepant for migraine prophylaxis in adults with a history of inadequate response to oral preventive medications
- Trial name
- NCT05518123
- Testing
- Rimegepant
- Where
- 111 sites in United States, Australia and 12 more
- Volunteers
- 962 people
- Sponsor
- Pfizer
Migraine
Home-based Biofeedback for the Prevention of Migraine
The goal of this clinical trial is to test an app-based biofeedback treatment in adults with migraine. The aim of the study is to investigate the safety and effectiveness of biofeedback treatment using the medical device Cerebri…
- Trial name
- BioCer (NCT05616741)
- Testing
- Cerebri biofeedback, Cerebri headache diary
- Where
- 4 sites in Norway
- Volunteers
- 279 people
- Sponsor
- Nordic Brain Tech AS
Migraine
Topical Intra-Oral Ketoprofen for Migraine Prevention
Intra-Oral Topical Ketoprofen gel, applied to a branch of the trigeminal nerve, has been shown to prevent migraines when used once daily for 3 months in open label studies.
- Trial name
- NCT01211795
- Testing
- topical intraoral ketoprofen gel
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Behar, Caren, M.D.
Episodic Migraine
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing episodic migraine.
- Trial name
- E-BEOND (NCT06047457)
- Testing
- Botulinum toxin type A
- Where
- 105 sites in United States, Canada and 6 more
- Volunteers
- 751 people
- Sponsor
- Ipsen
Migraine Disorders
Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old
A Phase 4 study to evaluate Qudexy XR for the prevention of migraine in children 6 to 11 years of age.
- Trial name
- NCT04748601
- Testing
- Qudexy XR
- Where
- 15 sites in United States
- Volunteers
- 132 people
- Sponsor
- Upsher-Smith Laboratories
Chronic Migraine
Non-Invasive Neurostimulation for the Prevention of Chronic Migraine
The purpose of this multi-center, prospective, double-blind, randomized, sham-controlled pilot study is to study feasibility and collect preliminary clinical data related to the safety and clinical benefits of daily use of…
- Trial name
- NCT01667250
- Testing
- GammaCore Active Device
- Where
- 6 sites in United States
- Volunteers
- 59 people
- Sponsor
- ElectroCore INC